Literature DB >> 29291766

Increasing diversion of methadone in Vancouver, Canada, 2005-2015.

Hudson Reddon1, Joel Ho2, Kora DeBeck3, M-J Milloy4, Yang Liu5, Huiru Dong6, Keith Ahamad7, Evan Wood4, Thomas Kerr4, Kanna Hayashi8.   

Abstract

BACKGROUND AND AIM: Although methadone, an opioid agonist, has been an effective medication used to treat opioid use disorder for over 40years, recent studies have found that methadone was identified in more than a quarter of prescription opioid-related deaths among people who use illicit drugs in Vancouver, Canada. Thus, we sought to longitudinally examine the availability of diverted methadone among people who inject drugs (PWID). DESIGN AND METHODS: Data were collected from three prospective cohorts of PWID in Vancouver, Canada between December 2005 and May 2015. Multivariable generalized estimating equation logistic regression was used to identify temporal trends in the immediate availability of diverted methadone (defined as the ability to acquire illicit methadone in <10min).
RESULTS: A total of 2092 participants, including 727 (34.8%) women, were included in the present study. In the multivariable analyses after adjusting for a range of potential confounders, later calendar year (adjusted odds ratio [AOR]=1.21 per year; 95% confidence interval [CI]: 1.19-1.23) was independently and positively associated with reporting immediate availability of diverted methadone.
CONCLUSIONS: We observed a significant increase in the reported availability of diverted methadone among PWID over a ten-year follow-up period. Further research is needed to identify strategies to limit methadone diversion and assess the impact of alternative medications that are equally effective but safer, such as buprenorphine/naloxone.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diversion; Illicit drug use; Methadone; Opioid; Overdose

Mesh:

Substances:

Year:  2017        PMID: 29291766      PMCID: PMC5753607          DOI: 10.1016/j.jsat.2017.11.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  59 in total

1.  [More and more methadone deaths. "Leakage" from ongoing more liberal treatment programs might be a cause].

Authors:  Anna Fugelstad; Age Johansson Lars; Ingemar Thiblin
Journal:  Lakartidningen       Date:  2010 May 5-11

2.  High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009.

Authors:  Benedikt Fischer; Wayne Jones; Jürgen Rehm
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-14       Impact factor: 2.890

3.  Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users.

Authors:  Thomas Kerr; Nadia Fairbairn; Mark Tyndall; David Marsh; Kathy Li; Julio Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2006-09-07       Impact factor: 4.492

4.  Trends and sex differences in prescription opioid deaths in British Columbia, Canada.

Authors:  Emilie J Gladstone; Kate Smolina; Steven G Morgan
Journal:  Inj Prev       Date:  2015-07-20       Impact factor: 2.399

5.  Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Kevin E O'Grady; Robert P Schwartz
Journal:  Am J Addict       Date:  2009 Sep-Oct

6.  The role of methadone in drug-related deaths in the west of Scotland.

Authors:  Alison Seymour; Marjorie Black; Jane Jay; Gail Cooper; Christopher Weir; John Oliver
Journal:  Addiction       Date:  2003-07       Impact factor: 6.526

7.  Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions.

Authors:  Courtney L Breen; Simon J Harris; Nicholas Lintzeris; Richard P Mattick; Lynn Hawken; James Bell; Alison J Ritter; Michael Lenné; Elizabeth Mendoza
Journal:  Drug Alcohol Depend       Date:  2003-07-20       Impact factor: 4.492

8.  Effects of buprenorphine and methadone in methadone-maintained subjects.

Authors:  S L Walsh; H L June; K J Schuh; K L Preston; G E Bigelow; M L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

Review 9.  Opioid agonist treatment for pharmaceutical opioid dependent people.

Authors:  Suzanne Nielsen; Briony Larance; Louisa Degenhardt; Linda Gowing; Chyanne Kehler; Nicholas Lintzeris
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

10.  Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.

Authors:  Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner
Journal:  BMJ       Date:  2009-04-30
View more
  5 in total

1.  Characteristics Associated with Nonmedical Methadone Use among People Who Inject Drugs in California.

Authors:  Johnathan K Zhao; Alex H Kral; Lynn D Wenger; Ricky N Bluthenthal
Journal:  Subst Use Misuse       Date:  2019-10-14       Impact factor: 2.164

2.  Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model.

Authors:  Robert A Kleinman; Thomas D Brothers; Marlon Danilewitz; Anees Bahji
Journal:  J Addict Med       Date:  2022-01-11       Impact factor: 4.647

3.  Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.

Authors:  Paxton Bach; Misha Bawa; Cameron Grant; M J Milloy; Kanna Hayashi
Journal:  Int J Drug Policy       Date:  2021-12-05

4.  Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.

Authors:  Björn Johnson; Torkel Richert
Journal:  Harm Reduct J       Date:  2019-05-02

5.  Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.

Authors:  Eugenia Oviedo-Joekes; Scott MacDonald; Charles Boissonneault; Kelli Harper
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.